Real-time Estimate Cboe BZX 02:18:40 2024-03-28 pm EDT 5-day change 1st Jan Change
29.28 USD +0.12% Intraday chart for Omnicell, Inc. +2.88% -22.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Omnicell, Inc. Announces Executive Changes CI
Wells Fargo Adjusts Price Target on Omnicell to $26 From $28, Maintains Equal-Weight Rating MT
Omnicell Fiscal Q4 Non-GAAP Net Income Flat, Revenue Falls; Sets Outlook MT
Transcript : Omnicell, Inc., Q4 2023 Earnings Call, Feb 08, 2024
(OMCL) OMNICELL Sees Q1 Revenue Range $232M - $242M MT
(OMCL) OMNICELL Expects Fiscal Year 2024 EPS Range $0.90 - $1.40 MT
Earnings Flash (OMCL) OMNICELL Reports Q4 Revenue $258.8M, vs. Street Est of $255.6M MT
Omnicell, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Fiscal Year 2024 CI
Earnings Flash (OMCL) OMNICELL Posts Q4 EPS $0.33, vs. Street Est of $0.15 MT
Omnicell, Inc. Reports Unaudited Impairment Changes Results for the Fourth Quarter Ended December 31, 2023 CI
Omnicell, Inc. Announces Board Changes CI
North American Morning Briefing : Stocks Look to -2- DJ
Tranche Update on Omnicell, Inc.'s Equity Buyback Plan announced on August 5, 2016. CI
Piper Sandler Upgrades Omnicell to Overweight From Neutral, Cuts Price Target to $39 From $70 MT
BTIG Downgrades Omnicell to Neutral From Buy MT
Wells Fargo Upgrades Omnicell to Equal-Weight From Underweight, Adjusts Price Target to $28 From $39 MT
Transcript : Omnicell, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (OMCL) OMNICELL Posts Q3 EPS $0.62, vs. Street Est of $0.48 MT
Earnings Flash (OMCL) OMNICELL Reports Q3 Revenue $298.7M, vs. Street Est of $297.2M MT
(OMCL) OMNICELL Forecasts Fiscal Year 2023 EPS Range $1.65 - $1.80 MT
(OMCL) OMNICELL Expects Q4 Revenue Range $247M - $267M MT
Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 CI
Omnicell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Mood Lifted on -2- DJ
Chart Omnicell, Inc.
More charts
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
29.24 USD
Average target price
33.29 USD
Spread / Average Target
+13.84%
Consensus
  1. Stock
  2. Equities
  3. Stock Omnicell, Inc. - Nasdaq
  4. News Omnicell, Inc.
  5. Omnicell : Berenberg Bank Adjusts Omnicell PT to $168 From $152, Maintains Buy Rating